nodes	percent_of_prediction	percent_of_DWPC	metapath
Dinoprostone—ABCC5—Fluorouracil—pancreatic cancer	0.133	0.203	CbGbCtD
Dinoprostone—SLCO2B1—Erlotinib—pancreatic cancer	0.0962	0.147	CbGbCtD
Dinoprostone—CYP19A1—Tamoxifen—pancreatic cancer	0.0793	0.121	CbGbCtD
Dinoprostone—SLC22A7—Fluorouracil—pancreatic cancer	0.0652	0.0997	CbGbCtD
Dinoprostone—ABCC4—Fluorouracil—pancreatic cancer	0.0637	0.0974	CbGbCtD
Dinoprostone—SLC22A7—Docetaxel—pancreatic cancer	0.0498	0.0761	CbGbCtD
Dinoprostone—ABCC4—Sunitinib—pancreatic cancer	0.0484	0.0741	CbGbCtD
Dinoprostone—SLCO1B1—Irinotecan—pancreatic cancer	0.0449	0.0687	CbGbCtD
Dinoprostone—CYP1A2—Dacarbazine—pancreatic cancer	0.0241	0.0369	CbGbCtD
Dinoprostone—CYP1A2—Tamoxifen—pancreatic cancer	0.0192	0.0293	CbGbCtD
Dinoprostone—CYP1A2—Erlotinib—pancreatic cancer	0.0163	0.0249	CbGbCtD
Dinoprostone—CYP1A2—Fluorouracil—pancreatic cancer	0.0141	0.0216	CbGbCtD
Dinoprostone—SLC51B—digestive system—pancreatic cancer	0.0018	0.0897	CbGeAlD
Dinoprostone—PTGER1—pancreas—pancreatic cancer	0.00149	0.074	CbGeAlD
Dinoprostone—PTGER4—digestive system—pancreatic cancer	0.00131	0.0655	CbGeAlD
Dinoprostone—SLC51A—digestive system—pancreatic cancer	0.00129	0.0643	CbGeAlD
Dinoprostone—SLCO2A1—islet of Langerhans—pancreatic cancer	0.00114	0.0569	CbGeAlD
Dinoprostone—HPGDS—pancreas—pancreatic cancer	0.00113	0.0561	CbGeAlD
Dinoprostone—PTGER3—digestive system—pancreatic cancer	0.00111	0.0554	CbGeAlD
Dinoprostone—SLCO4A1—islet of Langerhans—pancreatic cancer	0.00105	0.0523	CbGeAlD
Dinoprostone—HPGDS—digestive system—pancreatic cancer	0.000961	0.0479	CbGeAlD
Dinoprostone—PTGIR—pancreas—pancreatic cancer	0.000917	0.0457	CbGeAlD
Dinoprostone—SLCO2A1—pancreas—pancreatic cancer	0.000802	0.04	CbGeAlD
Dinoprostone—PTGIR—digestive system—pancreatic cancer	0.000784	0.0391	CbGeAlD
Dinoprostone—SLC22A11—digestive system—pancreatic cancer	0.000764	0.0381	CbGeAlD
Dinoprostone—SLC22A7—digestive system—pancreatic cancer	0.000745	0.0372	CbGeAlD
Dinoprostone—SLCO4A1—pancreas—pancreatic cancer	0.000738	0.0368	CbGeAlD
Dinoprostone—SLC22A2—digestive system—pancreatic cancer	0.000663	0.0331	CbGeAlD
Dinoprostone—SLCO4A1—digestive system—pancreatic cancer	0.00063	0.0314	CbGeAlD
Dinoprostone—SLCO1B1—digestive system—pancreatic cancer	0.000554	0.0276	CbGeAlD
Dinoprostone—ABCC4—pancreas—pancreatic cancer	0.000508	0.0253	CbGeAlD
Dinoprostone—SLCO2B1—digestive system—pancreatic cancer	0.00049	0.0244	CbGeAlD
Dinoprostone—SLCO1A2—digestive system—pancreatic cancer	0.000451	0.0225	CbGeAlD
Dinoprostone—ABCC4—digestive system—pancreatic cancer	0.000434	0.0216	CbGeAlD
Dinoprostone—Arrhythmia—Irinotecan—pancreatic cancer	0.000403	0.00311	CcSEcCtD
Dinoprostone—Dyspnoea—Erlotinib—pancreatic cancer	0.0004	0.00309	CcSEcCtD
Dinoprostone—Inflammation—Doxorubicin—pancreatic cancer	0.000399	0.00308	CcSEcCtD
Dinoprostone—Angiopathy—Gemcitabine—pancreatic cancer	0.000398	0.00308	CcSEcCtD
Dinoprostone—Immune system disorder—Gemcitabine—pancreatic cancer	0.000397	0.00306	CcSEcCtD
Dinoprostone—Vaginal infection—Epirubicin—pancreatic cancer	0.000395	0.00305	CcSEcCtD
Dinoprostone—Chills—Gemcitabine—pancreatic cancer	0.000394	0.00304	CcSEcCtD
Dinoprostone—Arrhythmia—Gemcitabine—pancreatic cancer	0.000392	0.00303	CcSEcCtD
Dinoprostone—Pain—Tamoxifen—pancreatic cancer	0.000388	0.003	CcSEcCtD
Dinoprostone—Hiccups—Doxorubicin—pancreatic cancer	0.000387	0.00299	CcSEcCtD
Dinoprostone—Vaginal inflammation—Doxorubicin—pancreatic cancer	0.000387	0.00299	CcSEcCtD
Dinoprostone—Arrhythmia—Fluorouracil—pancreatic cancer	0.000386	0.00298	CcSEcCtD
Dinoprostone—Cramps of lower extremities—Epirubicin—pancreatic cancer	0.000384	0.00297	CcSEcCtD
Dinoprostone—Pain—Erlotinib—pancreatic cancer	0.000384	0.00297	CcSEcCtD
Dinoprostone—Bronchospasm—Docetaxel—pancreatic cancer	0.000383	0.00296	CcSEcCtD
Dinoprostone—Shock—Sunitinib—pancreatic cancer	0.000382	0.00296	CcSEcCtD
Dinoprostone—Back pain—Irinotecan—pancreatic cancer	0.00038	0.00293	CcSEcCtD
Dinoprostone—Muscle spasms—Irinotecan—pancreatic cancer	0.000377	0.00292	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.000371	0.00287	CcSEcCtD
Dinoprostone—Back pain—Gemcitabine—pancreatic cancer	0.00037	0.00286	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.000367	0.00284	CcSEcCtD
Dinoprostone—Hypertonia—Epirubicin—pancreatic cancer	0.000367	0.00283	CcSEcCtD
Dinoprostone—Vaginal infection—Doxorubicin—pancreatic cancer	0.000366	0.00282	CcSEcCtD
Dinoprostone—Abdominal pain—Tamoxifen—pancreatic cancer	0.000359	0.00277	CcSEcCtD
Dinoprostone—Cramps of lower extremities—Doxorubicin—pancreatic cancer	0.000356	0.00275	CcSEcCtD
Dinoprostone—Abdominal pain—Erlotinib—pancreatic cancer	0.000355	0.00274	CcSEcCtD
Dinoprostone—Body temperature increased—Erlotinib—pancreatic cancer	0.000355	0.00274	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.000354	0.00274	CcSEcCtD
Dinoprostone—Vision blurred—Fluorouracil—pancreatic cancer	0.000354	0.00274	CcSEcCtD
Dinoprostone—Syncope—Irinotecan—pancreatic cancer	0.000352	0.00272	CcSEcCtD
Dinoprostone—Paraesthesia—Sunitinib—pancreatic cancer	0.000349	0.0027	CcSEcCtD
Dinoprostone—Dyspnoea—Sunitinib—pancreatic cancer	0.000347	0.00268	CcSEcCtD
Dinoprostone—Loss of consciousness—Irinotecan—pancreatic cancer	0.000345	0.00266	CcSEcCtD
Dinoprostone—Cough—Irinotecan—pancreatic cancer	0.000342	0.00265	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Docetaxel—pancreatic cancer	0.000342	0.00264	CcSEcCtD
Dinoprostone—Myocardial infarction—Docetaxel—pancreatic cancer	0.00034	0.00263	CcSEcCtD
Dinoprostone—Hypertonia—Doxorubicin—pancreatic cancer	0.000339	0.00262	CcSEcCtD
Dinoprostone—Hypertension—Irinotecan—pancreatic cancer	0.000339	0.00262	CcSEcCtD
Dinoprostone—Eye pain—Epirubicin—pancreatic cancer	0.000337	0.0026	CcSEcCtD
Dinoprostone—Hypersensitivity—Tamoxifen—pancreatic cancer	0.000334	0.00258	CcSEcCtD
Dinoprostone—Cough—Gemcitabine—pancreatic cancer	0.000334	0.00258	CcSEcCtD
Dinoprostone—Pain—Sunitinib—pancreatic cancer	0.000332	0.00257	CcSEcCtD
Dinoprostone—Hypertension—Gemcitabine—pancreatic cancer	0.00033	0.00255	CcSEcCtD
Dinoprostone—Asthenia—Tamoxifen—pancreatic cancer	0.000326	0.00252	CcSEcCtD
Dinoprostone—Arthralgia—Gemcitabine—pancreatic cancer	0.000325	0.00251	CcSEcCtD
Dinoprostone—Myalgia—Gemcitabine—pancreatic cancer	0.000325	0.00251	CcSEcCtD
Dinoprostone—Chest pain—Gemcitabine—pancreatic cancer	0.000325	0.00251	CcSEcCtD
Dinoprostone—Hot flush—Epirubicin—pancreatic cancer	0.000325	0.00251	CcSEcCtD
Dinoprostone—Asthenia—Erlotinib—pancreatic cancer	0.000322	0.00249	CcSEcCtD
Dinoprostone—Menopausal symptoms—Epirubicin—pancreatic cancer	0.000322	0.00249	CcSEcCtD
Dinoprostone—Anaphylactic shock—Irinotecan—pancreatic cancer	0.00032	0.00247	CcSEcCtD
Dinoprostone—Myalgia—Fluorouracil—pancreatic cancer	0.00032	0.00247	CcSEcCtD
Dinoprostone—Chest pain—Fluorouracil—pancreatic cancer	0.00032	0.00247	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000318	0.00246	CcSEcCtD
Dinoprostone—Shock—Irinotecan—pancreatic cancer	0.000315	0.00243	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Epirubicin—pancreatic cancer	0.000314	0.00243	CcSEcCtD
Dinoprostone—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.000312	0.00241	CcSEcCtD
Dinoprostone—Eye pain—Doxorubicin—pancreatic cancer	0.000311	0.00241	CcSEcCtD
Dinoprostone—Diarrhoea—Tamoxifen—pancreatic cancer	0.000311	0.0024	CcSEcCtD
Dinoprostone—Hyperhidrosis—Irinotecan—pancreatic cancer	0.00031	0.00239	CcSEcCtD
Dinoprostone—Pharyngitis—Docetaxel—pancreatic cancer	0.000309	0.00239	CcSEcCtD
Dinoprostone—Abdominal pain—Sunitinib—pancreatic cancer	0.000307	0.00237	CcSEcCtD
Dinoprostone—Body temperature increased—Sunitinib—pancreatic cancer	0.000307	0.00237	CcSEcCtD
Dinoprostone—Diarrhoea—Erlotinib—pancreatic cancer	0.000307	0.00237	CcSEcCtD
Dinoprostone—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.000307	0.00237	CcSEcCtD
Dinoprostone—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.000302	0.00233	CcSEcCtD
Dinoprostone—Hot flush—Doxorubicin—pancreatic cancer	0.0003	0.00232	CcSEcCtD
Dinoprostone—Dizziness—Tamoxifen—pancreatic cancer	0.0003	0.00232	CcSEcCtD
Dinoprostone—Tachycardia—Fluorouracil—pancreatic cancer	0.000299	0.00231	CcSEcCtD
Dinoprostone—Hypotension—Irinotecan—pancreatic cancer	0.000299	0.00231	CcSEcCtD
Dinoprostone—Menopausal symptoms—Doxorubicin—pancreatic cancer	0.000298	0.0023	CcSEcCtD
Dinoprostone—Dizziness—Erlotinib—pancreatic cancer	0.000297	0.00229	CcSEcCtD
Dinoprostone—CYP1A2—digestive system—pancreatic cancer	0.000295	0.0147	CbGeAlD
Dinoprostone—Hypotension—Gemcitabine—pancreatic cancer	0.000291	0.00225	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Doxorubicin—pancreatic cancer	0.00029	0.00224	CcSEcCtD
Dinoprostone—Flushing—Docetaxel—pancreatic cancer	0.000289	0.00223	CcSEcCtD
Dinoprostone—Cardiac arrest—Epirubicin—pancreatic cancer	0.000289	0.00223	CcSEcCtD
Dinoprostone—Vomiting—Tamoxifen—pancreatic cancer	0.000289	0.00223	CcSEcCtD
Dinoprostone—Paraesthesia—Irinotecan—pancreatic cancer	0.000288	0.00222	CcSEcCtD
Dinoprostone—Hypotension—Fluorouracil—pancreatic cancer	0.000287	0.00221	CcSEcCtD
Dinoprostone—Hypersensitivity—Sunitinib—pancreatic cancer	0.000286	0.00221	CcSEcCtD
Dinoprostone—Rash—Tamoxifen—pancreatic cancer	0.000286	0.00221	CcSEcCtD
Dinoprostone—Dermatitis—Tamoxifen—pancreatic cancer	0.000286	0.00221	CcSEcCtD
Dinoprostone—Vomiting—Erlotinib—pancreatic cancer	0.000286	0.00221	CcSEcCtD
Dinoprostone—Dyspnoea—Irinotecan—pancreatic cancer	0.000286	0.00221	CcSEcCtD
Dinoprostone—Headache—Tamoxifen—pancreatic cancer	0.000284	0.0022	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000284	0.0022	CcSEcCtD
Dinoprostone—Rash—Erlotinib—pancreatic cancer	0.000283	0.00219	CcSEcCtD
Dinoprostone—Dermatitis—Erlotinib—pancreatic cancer	0.000283	0.00219	CcSEcCtD
Dinoprostone—Angiopathy—Docetaxel—pancreatic cancer	0.000283	0.00218	CcSEcCtD
Dinoprostone—Dehydration—Epirubicin—pancreatic cancer	0.000283	0.00218	CcSEcCtD
Dinoprostone—Immune system disorder—Docetaxel—pancreatic cancer	0.000281	0.00217	CcSEcCtD
Dinoprostone—Headache—Erlotinib—pancreatic cancer	0.000281	0.00217	CcSEcCtD
Dinoprostone—Paraesthesia—Gemcitabine—pancreatic cancer	0.00028	0.00216	CcSEcCtD
Dinoprostone—Chills—Docetaxel—pancreatic cancer	0.00028	0.00216	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000279	0.00216	CcSEcCtD
Dinoprostone—Asthenia—Sunitinib—pancreatic cancer	0.000279	0.00216	CcSEcCtD
Dinoprostone—Arrhythmia—Docetaxel—pancreatic cancer	0.000278	0.00215	CcSEcCtD
Dinoprostone—Dyspnoea—Gemcitabine—pancreatic cancer	0.000278	0.00215	CcSEcCtD
Dinoprostone—Paraesthesia—Fluorouracil—pancreatic cancer	0.000275	0.00213	CcSEcCtD
Dinoprostone—Pain—Irinotecan—pancreatic cancer	0.000274	0.00212	CcSEcCtD
Dinoprostone—Dyspnoea—Fluorouracil—pancreatic cancer	0.000273	0.00211	CcSEcCtD
Dinoprostone—Nausea—Tamoxifen—pancreatic cancer	0.00027	0.00208	CcSEcCtD
Dinoprostone—Cardiac arrest—Doxorubicin—pancreatic cancer	0.000267	0.00207	CcSEcCtD
Dinoprostone—Pain—Gemcitabine—pancreatic cancer	0.000267	0.00206	CcSEcCtD
Dinoprostone—Nausea—Erlotinib—pancreatic cancer	0.000267	0.00206	CcSEcCtD
Dinoprostone—Diarrhoea—Sunitinib—pancreatic cancer	0.000266	0.00206	CcSEcCtD
Dinoprostone—Asthma—Epirubicin—pancreatic cancer	0.000263	0.00203	CcSEcCtD
Dinoprostone—Back pain—Docetaxel—pancreatic cancer	0.000262	0.00203	CcSEcCtD
Dinoprostone—Pain—Fluorouracil—pancreatic cancer	0.000262	0.00203	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000262	0.00202	CcSEcCtD
Dinoprostone—Dehydration—Doxorubicin—pancreatic cancer	0.000261	0.00202	CcSEcCtD
Dinoprostone—Muscle spasms—Docetaxel—pancreatic cancer	0.000261	0.00202	CcSEcCtD
Dinoprostone—Dizziness—Sunitinib—pancreatic cancer	0.000257	0.00199	CcSEcCtD
Dinoprostone—Body temperature increased—Irinotecan—pancreatic cancer	0.000253	0.00196	CcSEcCtD
Dinoprostone—Abdominal pain—Irinotecan—pancreatic cancer	0.000253	0.00196	CcSEcCtD
Dinoprostone—Vomiting—Sunitinib—pancreatic cancer	0.000247	0.00191	CcSEcCtD
Dinoprostone—Body temperature increased—Gemcitabine—pancreatic cancer	0.000247	0.00191	CcSEcCtD
Dinoprostone—Rash—Sunitinib—pancreatic cancer	0.000245	0.00189	CcSEcCtD
Dinoprostone—Dermatitis—Sunitinib—pancreatic cancer	0.000245	0.00189	CcSEcCtD
Dinoprostone—Headache—Sunitinib—pancreatic cancer	0.000244	0.00188	CcSEcCtD
Dinoprostone—Syncope—Docetaxel—pancreatic cancer	0.000243	0.00188	CcSEcCtD
Dinoprostone—Asthma—Doxorubicin—pancreatic cancer	0.000243	0.00188	CcSEcCtD
Dinoprostone—Body temperature increased—Fluorouracil—pancreatic cancer	0.000242	0.00187	CcSEcCtD
Dinoprostone—Loss of consciousness—Docetaxel—pancreatic cancer	0.000238	0.00184	CcSEcCtD
Dinoprostone—Cough—Docetaxel—pancreatic cancer	0.000237	0.00183	CcSEcCtD
Dinoprostone—Hypersensitivity—Irinotecan—pancreatic cancer	0.000236	0.00182	CcSEcCtD
Dinoprostone—Hypertension—Docetaxel—pancreatic cancer	0.000234	0.00181	CcSEcCtD
Dinoprostone—Myalgia—Docetaxel—pancreatic cancer	0.000231	0.00178	CcSEcCtD
Dinoprostone—Chest pain—Docetaxel—pancreatic cancer	0.000231	0.00178	CcSEcCtD
Dinoprostone—Arthralgia—Docetaxel—pancreatic cancer	0.000231	0.00178	CcSEcCtD
Dinoprostone—Nausea—Sunitinib—pancreatic cancer	0.000231	0.00178	CcSEcCtD
Dinoprostone—Asthenia—Irinotecan—pancreatic cancer	0.00023	0.00178	CcSEcCtD
Dinoprostone—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000226	0.00175	CcSEcCtD
Dinoprostone—Asthenia—Gemcitabine—pancreatic cancer	0.000224	0.00173	CcSEcCtD
Dinoprostone—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000221	0.00171	CcSEcCtD
Dinoprostone—Diarrhoea—Irinotecan—pancreatic cancer	0.000219	0.00169	CcSEcCtD
Dinoprostone—Shock—Docetaxel—pancreatic cancer	0.000218	0.00168	CcSEcCtD
Dinoprostone—Tachycardia—Docetaxel—pancreatic cancer	0.000216	0.00167	CcSEcCtD
Dinoprostone—Diarrhoea—Gemcitabine—pancreatic cancer	0.000213	0.00165	CcSEcCtD
Dinoprostone—Dizziness—Irinotecan—pancreatic cancer	0.000212	0.00164	CcSEcCtD
Dinoprostone—Diarrhoea—Fluorouracil—pancreatic cancer	0.00021	0.00162	CcSEcCtD
Dinoprostone—Pharyngitis—Epirubicin—pancreatic cancer	0.000209	0.00161	CcSEcCtD
Dinoprostone—Hypotension—Docetaxel—pancreatic cancer	0.000207	0.0016	CcSEcCtD
Dinoprostone—Vomiting—Irinotecan—pancreatic cancer	0.000204	0.00157	CcSEcCtD
Dinoprostone—Dizziness—Fluorouracil—pancreatic cancer	0.000203	0.00157	CcSEcCtD
Dinoprostone—Rash—Irinotecan—pancreatic cancer	0.000202	0.00156	CcSEcCtD
Dinoprostone—Dermatitis—Irinotecan—pancreatic cancer	0.000202	0.00156	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000202	0.00156	CcSEcCtD
Dinoprostone—Headache—Irinotecan—pancreatic cancer	0.000201	0.00155	CcSEcCtD
Dinoprostone—Paraesthesia—Docetaxel—pancreatic cancer	0.000199	0.00154	CcSEcCtD
Dinoprostone—Vomiting—Gemcitabine—pancreatic cancer	0.000198	0.00153	CcSEcCtD
Dinoprostone—Dyspnoea—Docetaxel—pancreatic cancer	0.000197	0.00153	CcSEcCtD
Dinoprostone—Rash—Gemcitabine—pancreatic cancer	0.000197	0.00152	CcSEcCtD
Dinoprostone—Dermatitis—Gemcitabine—pancreatic cancer	0.000197	0.00152	CcSEcCtD
Dinoprostone—Headache—Gemcitabine—pancreatic cancer	0.000195	0.00151	CcSEcCtD
Dinoprostone—Flushing—Epirubicin—pancreatic cancer	0.000195	0.00151	CcSEcCtD
Dinoprostone—Vomiting—Fluorouracil—pancreatic cancer	0.000195	0.00151	CcSEcCtD
Dinoprostone—Rash—Fluorouracil—pancreatic cancer	0.000193	0.00149	CcSEcCtD
Dinoprostone—Dermatitis—Fluorouracil—pancreatic cancer	0.000193	0.00149	CcSEcCtD
Dinoprostone—Pharyngitis—Doxorubicin—pancreatic cancer	0.000193	0.00149	CcSEcCtD
Dinoprostone—Headache—Fluorouracil—pancreatic cancer	0.000192	0.00148	CcSEcCtD
Dinoprostone—Angiopathy—Epirubicin—pancreatic cancer	0.000191	0.00147	CcSEcCtD
Dinoprostone—Nausea—Irinotecan—pancreatic cancer	0.00019	0.00147	CcSEcCtD
Dinoprostone—Immune system disorder—Epirubicin—pancreatic cancer	0.00019	0.00147	CcSEcCtD
Dinoprostone—Pain—Docetaxel—pancreatic cancer	0.000189	0.00146	CcSEcCtD
Dinoprostone—Chills—Epirubicin—pancreatic cancer	0.000189	0.00146	CcSEcCtD
Dinoprostone—Arrhythmia—Epirubicin—pancreatic cancer	0.000188	0.00145	CcSEcCtD
Dinoprostone—Nausea—Gemcitabine—pancreatic cancer	0.000185	0.00143	CcSEcCtD
Dinoprostone—Nausea—Fluorouracil—pancreatic cancer	0.000182	0.00141	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000181	0.0014	CcSEcCtD
Dinoprostone—Flushing—Doxorubicin—pancreatic cancer	0.00018	0.00139	CcSEcCtD
Dinoprostone—Tension—Epirubicin—pancreatic cancer	0.00018	0.00139	CcSEcCtD
Dinoprostone—Back pain—Epirubicin—pancreatic cancer	0.000177	0.00137	CcSEcCtD
Dinoprostone—Angiopathy—Doxorubicin—pancreatic cancer	0.000176	0.00136	CcSEcCtD
Dinoprostone—Muscle spasms—Epirubicin—pancreatic cancer	0.000176	0.00136	CcSEcCtD
Dinoprostone—Immune system disorder—Doxorubicin—pancreatic cancer	0.000176	0.00136	CcSEcCtD
Dinoprostone—Abdominal pain—Docetaxel—pancreatic cancer	0.000175	0.00135	CcSEcCtD
Dinoprostone—Body temperature increased—Docetaxel—pancreatic cancer	0.000175	0.00135	CcSEcCtD
Dinoprostone—Chills—Doxorubicin—pancreatic cancer	0.000174	0.00135	CcSEcCtD
Dinoprostone—Arrhythmia—Doxorubicin—pancreatic cancer	0.000174	0.00134	CcSEcCtD
Dinoprostone—Vision blurred—Epirubicin—pancreatic cancer	0.000172	0.00133	CcSEcCtD
Dinoprostone—Tension—Doxorubicin—pancreatic cancer	0.000166	0.00128	CcSEcCtD
Dinoprostone—Syncope—Epirubicin—pancreatic cancer	0.000164	0.00127	CcSEcCtD
Dinoprostone—Back pain—Doxorubicin—pancreatic cancer	0.000164	0.00127	CcSEcCtD
Dinoprostone—Hypersensitivity—Docetaxel—pancreatic cancer	0.000163	0.00126	CcSEcCtD
Dinoprostone—Muscle spasms—Doxorubicin—pancreatic cancer	0.000163	0.00126	CcSEcCtD
Dinoprostone—Loss of consciousness—Epirubicin—pancreatic cancer	0.000161	0.00124	CcSEcCtD
Dinoprostone—Cough—Epirubicin—pancreatic cancer	0.00016	0.00123	CcSEcCtD
Dinoprostone—Vision blurred—Doxorubicin—pancreatic cancer	0.00016	0.00123	CcSEcCtD
Dinoprostone—Asthenia—Docetaxel—pancreatic cancer	0.000159	0.00123	CcSEcCtD
Dinoprostone—Hypertension—Epirubicin—pancreatic cancer	0.000158	0.00122	CcSEcCtD
Dinoprostone—Myalgia—Epirubicin—pancreatic cancer	0.000156	0.0012	CcSEcCtD
Dinoprostone—Chest pain—Epirubicin—pancreatic cancer	0.000156	0.0012	CcSEcCtD
Dinoprostone—Arthralgia—Epirubicin—pancreatic cancer	0.000156	0.0012	CcSEcCtD
Dinoprostone—Syncope—Doxorubicin—pancreatic cancer	0.000152	0.00117	CcSEcCtD
Dinoprostone—Diarrhoea—Docetaxel—pancreatic cancer	0.000151	0.00117	CcSEcCtD
Dinoprostone—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000149	0.00115	CcSEcCtD
Dinoprostone—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000149	0.00115	CcSEcCtD
Dinoprostone—Cough—Doxorubicin—pancreatic cancer	0.000148	0.00114	CcSEcCtD
Dinoprostone—Shock—Epirubicin—pancreatic cancer	0.000147	0.00114	CcSEcCtD
Dinoprostone—Dizziness—Docetaxel—pancreatic cancer	0.000146	0.00113	CcSEcCtD
Dinoprostone—Hypertension—Doxorubicin—pancreatic cancer	0.000146	0.00113	CcSEcCtD
Dinoprostone—Tachycardia—Epirubicin—pancreatic cancer	0.000146	0.00113	CcSEcCtD
Dinoprostone—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000144	0.00112	CcSEcCtD
Dinoprostone—Arthralgia—Doxorubicin—pancreatic cancer	0.000144	0.00111	CcSEcCtD
Dinoprostone—Chest pain—Doxorubicin—pancreatic cancer	0.000144	0.00111	CcSEcCtD
Dinoprostone—Myalgia—Doxorubicin—pancreatic cancer	0.000144	0.00111	CcSEcCtD
Dinoprostone—Vomiting—Docetaxel—pancreatic cancer	0.000141	0.00109	CcSEcCtD
Dinoprostone—Rash—Docetaxel—pancreatic cancer	0.00014	0.00108	CcSEcCtD
Dinoprostone—Hypotension—Epirubicin—pancreatic cancer	0.00014	0.00108	CcSEcCtD
Dinoprostone—Dermatitis—Docetaxel—pancreatic cancer	0.000139	0.00108	CcSEcCtD
Dinoprostone—Headache—Docetaxel—pancreatic cancer	0.000139	0.00107	CcSEcCtD
Dinoprostone—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000138	0.00107	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000136	0.00105	CcSEcCtD
Dinoprostone—Shock—Doxorubicin—pancreatic cancer	0.000136	0.00105	CcSEcCtD
Dinoprostone—Tachycardia—Doxorubicin—pancreatic cancer	0.000135	0.00104	CcSEcCtD
Dinoprostone—Paraesthesia—Epirubicin—pancreatic cancer	0.000134	0.00104	CcSEcCtD
Dinoprostone—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000134	0.00103	CcSEcCtD
Dinoprostone—Dyspnoea—Epirubicin—pancreatic cancer	0.000133	0.00103	CcSEcCtD
Dinoprostone—Nausea—Docetaxel—pancreatic cancer	0.000131	0.00102	CcSEcCtD
Dinoprostone—Hypotension—Doxorubicin—pancreatic cancer	0.000129	0.000998	CcSEcCtD
Dinoprostone—Pain—Epirubicin—pancreatic cancer	0.000128	0.000987	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000126	0.000973	CcSEcCtD
Dinoprostone—Paraesthesia—Doxorubicin—pancreatic cancer	0.000124	0.000959	CcSEcCtD
Dinoprostone—Dyspnoea—Doxorubicin—pancreatic cancer	0.000123	0.000952	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000122	0.000943	CcSEcCtD
Dinoprostone—Pain—Doxorubicin—pancreatic cancer	0.000118	0.000913	CcSEcCtD
Dinoprostone—Body temperature increased—Epirubicin—pancreatic cancer	0.000118	0.000912	CcSEcCtD
Dinoprostone—Abdominal pain—Epirubicin—pancreatic cancer	0.000118	0.000912	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000113	0.000873	CcSEcCtD
Dinoprostone—Hypersensitivity—Epirubicin—pancreatic cancer	0.00011	0.00085	CcSEcCtD
Dinoprostone—Abdominal pain—Doxorubicin—pancreatic cancer	0.000109	0.000844	CcSEcCtD
Dinoprostone—Body temperature increased—Doxorubicin—pancreatic cancer	0.000109	0.000844	CcSEcCtD
Dinoprostone—Asthenia—Epirubicin—pancreatic cancer	0.000107	0.000828	CcSEcCtD
Dinoprostone—Diarrhoea—Epirubicin—pancreatic cancer	0.000102	0.000789	CcSEcCtD
Dinoprostone—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000102	0.000787	CcSEcCtD
Dinoprostone—Asthenia—Doxorubicin—pancreatic cancer	9.91e-05	0.000766	CcSEcCtD
Dinoprostone—Dizziness—Epirubicin—pancreatic cancer	9.87e-05	0.000763	CcSEcCtD
Dinoprostone—Vomiting—Epirubicin—pancreatic cancer	9.49e-05	0.000734	CcSEcCtD
Dinoprostone—Diarrhoea—Doxorubicin—pancreatic cancer	9.45e-05	0.00073	CcSEcCtD
Dinoprostone—Rash—Epirubicin—pancreatic cancer	9.41e-05	0.000727	CcSEcCtD
Dinoprostone—Dermatitis—Epirubicin—pancreatic cancer	9.41e-05	0.000727	CcSEcCtD
Dinoprostone—Headache—Epirubicin—pancreatic cancer	9.35e-05	0.000723	CcSEcCtD
Dinoprostone—Dizziness—Doxorubicin—pancreatic cancer	9.14e-05	0.000706	CcSEcCtD
Dinoprostone—Nausea—Epirubicin—pancreatic cancer	8.87e-05	0.000685	CcSEcCtD
Dinoprostone—Vomiting—Doxorubicin—pancreatic cancer	8.78e-05	0.000679	CcSEcCtD
Dinoprostone—Rash—Doxorubicin—pancreatic cancer	8.71e-05	0.000673	CcSEcCtD
Dinoprostone—Dermatitis—Doxorubicin—pancreatic cancer	8.7e-05	0.000672	CcSEcCtD
Dinoprostone—Headache—Doxorubicin—pancreatic cancer	8.66e-05	0.000669	CcSEcCtD
Dinoprostone—Nausea—Doxorubicin—pancreatic cancer	8.21e-05	0.000634	CcSEcCtD
Dinoprostone—Dihomo-gamma-linolenic acid—PTGS2—pancreatic cancer	3.26e-05	1	CrCbGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.42e-05	7.22e-05	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—EGFR—pancreatic cancer	1.42e-05	7.21e-05	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—TGFB1—pancreatic cancer	1.41e-05	7.17e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CASP3—pancreatic cancer	1.41e-05	7.16e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.41e-05	7.16e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—AKT1—pancreatic cancer	1.4e-05	7.11e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—GCG—pancreatic cancer	1.39e-05	7.07e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—STK11—pancreatic cancer	1.38e-05	7.03e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.38e-05	7.02e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—PIK3CB—pancreatic cancer	1.38e-05	7e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CCND1—pancreatic cancer	1.37e-05	6.97e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—PTGS2—pancreatic cancer	1.36e-05	6.93e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—EGFR—pancreatic cancer	1.36e-05	6.92e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CTNNB1—pancreatic cancer	1.36e-05	6.9e-05	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—PIK3CA—pancreatic cancer	1.36e-05	6.9e-05	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—KRAS—pancreatic cancer	1.34e-05	6.81e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—EGFR—pancreatic cancer	1.33e-05	6.77e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—EGFR—pancreatic cancer	1.33e-05	6.77e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—MMP9—pancreatic cancer	1.33e-05	6.76e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—SRC—pancreatic cancer	1.33e-05	6.76e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—CD44—pancreatic cancer	1.33e-05	6.76e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—PTEN—pancreatic cancer	1.32e-05	6.73e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PIK3CD—pancreatic cancer	1.32e-05	6.72e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PIK3CG—pancreatic cancer	1.32e-05	6.7e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—TYMS—pancreatic cancer	1.32e-05	6.69e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—PIK3CD—pancreatic cancer	1.31e-05	6.68e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PRSS1—pancreatic cancer	1.31e-05	6.67e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—STK11—pancreatic cancer	1.31e-05	6.65e-05	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—KRAS—pancreatic cancer	1.31e-05	6.65e-05	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.3e-05	6.61e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Neuronal System—HRAS—pancreatic cancer	1.3e-05	6.6e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.3e-05	6.6e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—VEGFA—pancreatic cancer	1.3e-05	6.58e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—AKT1—pancreatic cancer	1.29e-05	6.56e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—KRAS—pancreatic cancer	1.29e-05	6.54e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—PIK3CD—pancreatic cancer	1.29e-05	6.54e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—PIK3CD—pancreatic cancer	1.29e-05	6.54e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—STAT3—pancreatic cancer	1.28e-05	6.52e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—NRAS—pancreatic cancer	1.28e-05	6.5e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—GCG—pancreatic cancer	1.28e-05	6.48e-05	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.27e-05	6.47e-05	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.27e-05	6.47e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PPARG—pancreatic cancer	1.27e-05	6.46e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—KRAS—pancreatic cancer	1.26e-05	6.4e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—KRAS—pancreatic cancer	1.26e-05	6.4e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—CD44—pancreatic cancer	1.24e-05	6.3e-05	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—PIK3CA—pancreatic cancer	1.23e-05	6.26e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.23e-05	6.24e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—SRC—pancreatic cancer	1.23e-05	6.24e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—CTNNB1—pancreatic cancer	1.22e-05	6.2e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Neuronal System—HRAS—pancreatic cancer	1.21e-05	6.15e-05	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—PIK3CA—pancreatic cancer	1.2e-05	6.11e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—STK11—pancreatic cancer	1.2e-05	6.09e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—VEGFA—pancreatic cancer	1.2e-05	6.07e-05	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—TP53—pancreatic cancer	1.19e-05	6.06e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—MYC—pancreatic cancer	1.19e-05	6.06e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—PTEN—pancreatic cancer	1.19e-05	6.04e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—TYMS—pancreatic cancer	1.19e-05	6.04e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—TGFB1—pancreatic cancer	1.19e-05	6.04e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—GCG—pancreatic cancer	1.19e-05	6.04e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—STAT3—pancreatic cancer	1.18e-05	6.01e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—PIK3CA—pancreatic cancer	1.18e-05	6.01e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—NRAS—pancreatic cancer	1.18e-05	6e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—EGFR—pancreatic cancer	1.17e-05	5.92e-05	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—TP53—pancreatic cancer	1.16e-05	5.91e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PIK3CD—pancreatic cancer	1.16e-05	5.89e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—PIK3CA—pancreatic cancer	1.16e-05	5.88e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—PIK3CA—pancreatic cancer	1.16e-05	5.88e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PIK3CB—pancreatic cancer	1.15e-05	5.86e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—PIK3CB—pancreatic cancer	1.15e-05	5.82e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PTGS2—pancreatic cancer	1.14e-05	5.8e-05	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—HRAS—pancreatic cancer	1.14e-05	5.79e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—ARG2—pancreatic cancer	1.14e-05	5.79e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—TYMS—pancreatic cancer	1.13e-05	5.72e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—PIK3CB—pancreatic cancer	1.12e-05	5.7e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—PIK3CB—pancreatic cancer	1.12e-05	5.7e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—STK11—pancreatic cancer	1.12e-05	5.68e-05	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—HRAS—pancreatic cancer	1.11e-05	5.65e-05	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—AKT1—pancreatic cancer	1.11e-05	5.64e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—SRC—pancreatic cancer	1.1e-05	5.61e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—KRAS—pancreatic cancer	1.1e-05	5.6e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CXCL8—pancreatic cancer	1.1e-05	5.59e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—MYC—pancreatic cancer	1.1e-05	5.59e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—TGFB1—pancreatic cancer	1.1e-05	5.58e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—HRAS—pancreatic cancer	1.09e-05	5.56e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CXCL8—pancreatic cancer	1.08e-05	5.47e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CXCL8—pancreatic cancer	1.08e-05	5.47e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—EGFR—pancreatic cancer	1.08e-05	5.47e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—HRAS—pancreatic cancer	1.07e-05	5.44e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—HRAS—pancreatic cancer	1.07e-05	5.44e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—APOE—pancreatic cancer	1.07e-05	5.44e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—STAT3—pancreatic cancer	1.06e-05	5.41e-05	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR downstream signaling—AKT1—pancreatic cancer	1.06e-05	5.4e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—NRAS—pancreatic cancer	1.06e-05	5.39e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CASP3—pancreatic cancer	1.05e-05	5.35e-05	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—AKT1—pancreatic cancer	1.04e-05	5.29e-05	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—AKT1—pancreatic cancer	1.04e-05	5.29e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—TYMS—pancreatic cancer	1.03e-05	5.24e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CASP3—pancreatic cancer	1.03e-05	5.24e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CASP3—pancreatic cancer	1.03e-05	5.24e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CCND1—pancreatic cancer	1.03e-05	5.21e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—KRAS—pancreatic cancer	1.02e-05	5.16e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CTNNB1—pancreatic cancer	1.02e-05	5.16e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.01e-05	5.15e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—PIK3CA—pancreatic cancer	1.01e-05	5.14e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PIK3CB—pancreatic cancer	1.01e-05	5.13e-05	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—AKT1—pancreatic cancer	1.01e-05	5.11e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CCND1—pancreatic cancer	1e-05	5.1e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CCND1—pancreatic cancer	1e-05	5.1e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PTGS2—pancreatic cancer	1e-05	5.08e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PTEN—pancreatic cancer	9.96e-06	5.06e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—MMP9—pancreatic cancer	9.96e-06	5.06e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—TYMP—pancreatic cancer	9.95e-06	5.06e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CTNNB1—pancreatic cancer	9.94e-06	5.05e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CTNNB1—pancreatic cancer	9.94e-06	5.05e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—PTEN—pancreatic cancer	9.9e-06	5.03e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—MYC—pancreatic cancer	9.89e-06	5.02e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—TGFB1—pancreatic cancer	9.86e-06	5.01e-05	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—AKT1—pancreatic cancer	9.82e-06	4.99e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—TP53—pancreatic cancer	9.79e-06	4.97e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—MMP9—pancreatic cancer	9.75e-06	4.95e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—MMP9—pancreatic cancer	9.75e-06	4.95e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—PTEN—pancreatic cancer	9.69e-06	4.92e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—PTEN—pancreatic cancer	9.69e-06	4.92e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—APOE—pancreatic cancer	9.67e-06	4.92e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—EGFR—pancreatic cancer	9.67e-06	4.91e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PIK3CG—pancreatic cancer	9.66e-06	4.91e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—AKT1—pancreatic cancer	9.66e-06	4.91e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—TYMS—pancreatic cancer	9.61e-06	4.88e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—AKT1—pancreatic cancer	9.45e-06	4.8e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—AKT1—pancreatic cancer	9.45e-06	4.8e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—HRAS—pancreatic cancer	9.36e-06	4.76e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—PIK3CA—pancreatic cancer	9.34e-06	4.74e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PPARG—pancreatic cancer	9.32e-06	4.74e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—SRC—pancreatic cancer	9.18e-06	4.66e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	9.16e-06	4.65e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—APOE—pancreatic cancer	9.15e-06	4.65e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—KRAS—pancreatic cancer	9.14e-06	4.64e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—TP53—pancreatic cancer	9.03e-06	4.59e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—SRC—pancreatic cancer	8.98e-06	4.57e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—SRC—pancreatic cancer	8.98e-06	4.57e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—VEGFA—pancreatic cancer	8.94e-06	4.54e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—STAT3—pancreatic cancer	8.85e-06	4.5e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—NRAS—pancreatic cancer	8.83e-06	4.49e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—VEGFA—pancreatic cancer	8.75e-06	4.45e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—VEGFA—pancreatic cancer	8.75e-06	4.45e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PIK3CG—pancreatic cancer	8.73e-06	4.44e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PTEN—pancreatic cancer	8.73e-06	4.43e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—STAT3—pancreatic cancer	8.66e-06	4.4e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—STAT3—pancreatic cancer	8.66e-06	4.4e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	8.66e-06	4.4e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—NRAS—pancreatic cancer	8.64e-06	4.39e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—NRAS—pancreatic cancer	8.64e-06	4.39e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—HRAS—pancreatic cancer	8.64e-06	4.39e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PIK3CD—pancreatic cancer	8.49e-06	4.31e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PPARG—pancreatic cancer	8.43e-06	4.28e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—PIK3CA—pancreatic cancer	8.39e-06	4.26e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—APOE—pancreatic cancer	8.39e-06	4.26e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—AKT1—pancreatic cancer	8.27e-06	4.2e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PIK3CG—pancreatic cancer	8.26e-06	4.2e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—MYC—pancreatic cancer	8.23e-06	4.18e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	8.21e-06	4.17e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—TGFB1—pancreatic cancer	8.21e-06	4.17e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—MYC—pancreatic cancer	8.05e-06	4.09e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—MYC—pancreatic cancer	8.05e-06	4.09e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—EGFR—pancreatic cancer	8.05e-06	4.09e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—TGFB1—pancreatic cancer	8.03e-06	4.08e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—TGFB1—pancreatic cancer	8.03e-06	4.08e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GLP1R—pancreatic cancer	8.02e-06	4.08e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PPARG—pancreatic cancer	7.97e-06	4.05e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—DPYD—pancreatic cancer	7.89e-06	4.01e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—EGFR—pancreatic cancer	7.88e-06	4e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—EGFR—pancreatic cancer	7.88e-06	4e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—APOE—pancreatic cancer	7.82e-06	3.97e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—HRAS—pancreatic cancer	7.77e-06	3.95e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PIK3CD—pancreatic cancer	7.68e-06	3.9e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—AKT1—pancreatic cancer	7.63e-06	3.88e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—KRAS—pancreatic cancer	7.6e-06	3.86e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PIK3CG—pancreatic cancer	7.57e-06	3.85e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	7.49e-06	3.81e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—KRAS—pancreatic cancer	7.44e-06	3.78e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—KRAS—pancreatic cancer	7.44e-06	3.78e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	7.41e-06	3.77e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PIK3CB—pancreatic cancer	7.4e-06	3.76e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PTGS2—pancreatic cancer	7.33e-06	3.73e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PPARG—pancreatic cancer	7.31e-06	3.71e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PIK3CD—pancreatic cancer	7.26e-06	3.69e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	7.15e-06	3.64e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PIK3CG—pancreatic cancer	7.06e-06	3.58e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PIK3CA—pancreatic cancer	7.03e-06	3.57e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—PIK3CA—pancreatic cancer	6.98e-06	3.55e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—AKT1—pancreatic cancer	6.86e-06	3.48e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—PIK3CA—pancreatic cancer	6.83e-06	3.47e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—PIK3CA—pancreatic cancer	6.83e-06	3.47e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PPARG—pancreatic cancer	6.81e-06	3.46e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—TP53—pancreatic cancer	6.76e-06	3.43e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PIK3CB—pancreatic cancer	6.69e-06	3.4e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PIK3CD—pancreatic cancer	6.65e-06	3.38e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PTGS2—pancreatic cancer	6.63e-06	3.37e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—TP53—pancreatic cancer	6.61e-06	3.36e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—TP53—pancreatic cancer	6.61e-06	3.36e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	6.52e-06	3.31e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—HRAS—pancreatic cancer	6.46e-06	3.28e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PTEN—pancreatic cancer	6.4e-06	3.25e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PIK3CB—pancreatic cancer	6.33e-06	3.22e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—HRAS—pancreatic cancer	6.32e-06	3.21e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—HRAS—pancreatic cancer	6.32e-06	3.21e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PTGS2—pancreatic cancer	6.27e-06	3.19e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PIK3CD—pancreatic cancer	6.2e-06	3.15e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PIK3CA—pancreatic cancer	6.16e-06	3.13e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—CD44—pancreatic cancer	5.8e-06	2.95e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PIK3CB—pancreatic cancer	5.8e-06	2.95e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PTEN—pancreatic cancer	5.78e-06	2.94e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PTGS2—pancreatic cancer	5.75e-06	2.92e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—AKT1—pancreatic cancer	5.74e-06	2.92e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—AKT1—pancreatic cancer	5.7e-06	2.9e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	5.68e-06	2.89e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	5.63e-06	2.86e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—AKT1—pancreatic cancer	5.58e-06	2.84e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—AKT1—pancreatic cancer	5.58e-06	2.84e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GCG—pancreatic cancer	5.56e-06	2.83e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PTEN—pancreatic cancer	5.47e-06	2.78e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PIK3CB—pancreatic cancer	5.41e-06	2.75e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PTGS2—pancreatic cancer	5.36e-06	2.72e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—STK11—pancreatic cancer	5.23e-06	2.66e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—AKT1—pancreatic cancer	5.03e-06	2.56e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PTEN—pancreatic cancer	5.01e-06	2.55e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	4.91e-06	2.49e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PTEN—pancreatic cancer	4.67e-06	2.37e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PIK3CA—pancreatic cancer	4.51e-06	2.29e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—TYMS—pancreatic cancer	4.5e-06	2.29e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PIK3CA—pancreatic cancer	4.08e-06	2.07e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PIK3CA—pancreatic cancer	3.86e-06	1.96e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—AKT1—pancreatic cancer	3.69e-06	1.87e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—APOE—pancreatic cancer	3.66e-06	1.86e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PIK3CA—pancreatic cancer	3.54e-06	1.8e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.46e-06	1.76e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—AKT1—pancreatic cancer	3.33e-06	1.69e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	3.3e-06	1.68e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PIK3CA—pancreatic cancer	3.3e-06	1.67e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PPARG—pancreatic cancer	3.19e-06	1.62e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—AKT1—pancreatic cancer	3.15e-06	1.6e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	2.9e-06	1.47e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—AKT1—pancreatic cancer	2.89e-06	1.47e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—AKT1—pancreatic cancer	2.69e-06	1.37e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	2.53e-06	1.29e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PTGS2—pancreatic cancer	2.51e-06	1.27e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PTEN—pancreatic cancer	2.19e-06	1.11e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	1.54e-06	7.84e-06	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.26e-06	6.4e-06	CbGpPWpGaD
